Once all the domains are bound, [https://en.wikipedia.org/wiki/Nucleoside_triphosphate NTpS] binds to PP1C in the active site. NTpS refers to the phosphorylated serine (residue 259) located at the N-terminus of RAF. Once NTpS is bound, PP1C catalyzes the dephosphorylation of serine 259. NTpS is dephosphorylated to prevent the active dimeric RAF from inactivating and changing into its monomeric structure. The <scene name='95/952705/Pp1c_active_site/4'>NTpS active site</scene> is surrounded by hydrophobic and acidic regions along with the C-terminus. These regions are located on the surface of PP1C, whereas the active site is placed further into the structure. It is thought that these regions help the ligand bind to the active site by making interactions that will lead NTpS into the protein. There is still some uncertainty as to how the substrate selectivity works, but these regions could play an essential role in it. Specifically, the pS from NTpS would bind to the hydrophobic region on PP1C<ref name="Liau">PMID:35768504</ref>.
Once all the domains are bound, [https://en.wikipedia.org/wiki/Nucleoside_triphosphate NTpS] binds to PP1C in the active site. NTpS refers to the phosphorylated serine (residue 259) located at the N-terminus of RAF. Once NTpS is bound, PP1C catalyzes the dephosphorylation of serine 259. NTpS is dephosphorylated to prevent the active dimeric RAF from inactivating and changing into its monomeric structure. The <scene name='95/952705/Pp1c_active_site/4'>NTpS active site</scene> is surrounded by hydrophobic and acidic regions along with the C-terminus. These regions are located on the surface of PP1C, whereas the active site is placed further into the structure. It is thought that these regions help the ligand bind to the active site by making interactions that will lead NTpS into the protein. There is still some uncertainty as to how the substrate selectivity works, but these regions could play an essential role in it. Specifically, the pS from NTpS would bind to the hydrophobic region on PP1C<ref name="Liau">PMID:35768504</ref>.
NTpS can bind to the PP1C active site without PP1C also being bound to SHOC2 and MRAS, however, the catalytic activity is much slower and the reaction is less efficient. In order for NTpS to bind PP1C in the absence of the other two proteins, NTpS would need to be exposed from its binding site in the inactive RAF complex. RAS has to bind to RAF to expose the NTpS allowing PP1C and NTpS to bind.
NTpS can bind to the PP1C active site without PP1C also being bound to SHOC2 and MRAS, however, the catalytic activity is much slower and the reaction is less efficient. In order for NTpS to bind PP1C in the absence of the other two proteins, NTpS would need to be exposed from its binding site in the inactive RAF complex. RAS has to bind to RAF to expose the NTpS, allowing PP1C and NTpS to bind.
<scene name='95/952705/Pp1c_active_site/5'>TextToBeDisplayed</scene> '''let me know thought on the style of image'''
<scene name='95/952705/Pp1c_active_site/5'>TextToBeDisplayed</scene> '''let me know thought on the style of image'''
Revision as of 02:08, 17 April 2023
This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795.
To get started:
Click the edit this page tab at the top. Save the page after each step, then edit it again.
show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.
SHOC2-PP1C-MRAS is a regulatory protein and enzyme complex that is involved in regulating cell proliferation and division [1]. This complex regulates the vast RAS-MAPK signaling pathway through control of the initial RAF MAPKKK. This pathway is initially activated by the binding of a growth factor to a GTPase which initiates intracellular RAS activation, such as HRAS, NRAS, or KRAS.
[1]. RAS-GTPases are a family of monomeric G-proteins that function as molecular switches and are key in regulating parts of signaling cascades. The RAS molecular switch alternates between binding GTP for the active state and GDP to become inactive [1].
Figure 1. Schematic representation of RAS/RAF/MEK/ERK pathway after assembly of SHOC2-PP1C-MRAS complex.
After activation via an extracellular growth factor, the RAS-GTPase enzyme binds GTP, which recruits RAF to the cell membrane. RAF [2] is a kinase that stimulates a signaling cascade by phosphorylation of MAPK (also known as MEK in mammals), which activates downstream proteins such as ERK1 and ERK2, which subsequently activate nuclear transcription factors and kinases. The RAS/RAF/MEK/ERK pathway is a critical signaling cascade for activating transcription factors and regulating gene expression[3].
Structure
Overview
The protein combines three separate (see notes for more). SHOC2, PP1C, and MRAS, to form the active protein (SMP complex), as seen in Figure 2[4]. The SMP complex was determined via cryo-electron microscopy as well as x-ray diffraction. The overall architecture has PP1C and MRAS bound within the concave surface of SHOC2, leaving the catalytic site of PP1C and the GTP binding cleft in MRAS exposed.
SHOC2
Figure 2. Surface representation of SHOC2-PP1C-MRAS (PDB 7upi). SHOC2 (blue), PP1C (orange) and MRAS (green).
SHOC2 is a scaffolding protein which acts as a cradle to bind PP1C and MRAS [4], serving as an aggregation point to enable reciprocal interactions between these three signaling proteins. SHOC2 is a leucine rich repeat (LRR) protein consisting of 20 consecutive LRR motifs. LRR motifs form an extended β-sheet on the inner concave surface of SHOC2 with α-helices facing outward to facilitate binding of the protein complex. These LRR motifs result in a largely hydrophobic core within the concave region.[5].
PP1C
PP1C is the catalytic domain of the phosphatase enzyme PP1, which removes reversible phosphorylations from signaling proteins. PP1C is a serine/threonine phosphatase involved in signaling pathways that control cell growth, division, and metabolism (REF)and explain more, see notes.
MRAS
MRAS is a monomeric GTPase and is anchored in the cell membrane. When MRAS binds GTP, it becomes active and can only bind the complex once activated [4]. MRAS is a subvariant of the RAS protein and therefore shares most of its regulatory and effector interactions[6]. While other RAS variants bind in complex with SHOC2 and PP1 to allow it to have phosphatase activity, MRAS binds the tightest.
Switch I and II
A key feature in allowing MRAS to be in its active versus inactive state is the switches in MRAS. When MRAS is active, GTP is bound and the switches allow MRAS to be bound with PP1C. When MRAS is inactive, GDP is bound and the switches do not allow MRAS to bind to PP1C. The switches determine whether MRAS can bind to SHOC2-PP1C. The switches have to go through a conformational change to allow binding of SHOC2-PP1C to MRAS. The conformational change is needed because without it SHOC2-PP1C could bind to MRAS when MRAS is still inactive. This process would cause the SHOC2-PP1C-MRAS pathway to constantly be running. The switches and GDP/GTP help regulate this process.
This conformational change is caused by GTP replacing GDP. When GTP is bound, MRAS shifts and binds with the previously associated SHOC2-PP1C complex. When GDP is bound, switch II in MRAS is moved outward, which causes a steric clash with SHOC2 (Switch I and II with GDP). When GTP is bound, switch II in MRAS can form various hydrogen bonding, pi stacking and hydrophobic interactions with SHOC2[7](Switch I and II with GTP). When MRAS is bound to SHOC2-PP1C, switch I has an important role in making interactions with PP1C.
MRAS binds to SHOC2 exclusively through its concave LRRs[8], primarily by the descending loop and strands of LRR domains 2-10. Add his sentence thingPP1C binds with the ascending loops of the SHOC2 LRR regions, and is further engaged through the N-terminal region of SHOC2 which contains the RVxF motif[9]. The initial forming of the complex begins with SHOC2-PP1C engagement, then is completed and stabilized by the GTP-loaded MRAS binding[9]. Once associated with SHOC2, MRAS binds to PP1C. Binding to MRAS localizes the other two proteins to the RAS signaling regions of the membrane to begin cellular signaling[8].
Active Site
Once all the domains are bound, NTpS binds to PP1C in the active site. NTpS refers to the phosphorylated serine (residue 259) located at the N-terminus of RAF. Once NTpS is bound, PP1C catalyzes the dephosphorylation of serine 259. NTpS is dephosphorylated to prevent the active dimeric RAF from inactivating and changing into its monomeric structure. The NTpS active site is surrounded by hydrophobic and acidic regions along with the C-terminus. These regions are located on the surface of PP1C, whereas the active site is placed further into the structure. It is thought that these regions help the ligand bind to the active site by making interactions that will lead NTpS into the protein. There is still some uncertainty as to how the substrate selectivity works, but these regions could play an essential role in it. Specifically, the pS from NTpS would bind to the hydrophobic region on PP1C[10].
NTpS can bind to the PP1C active site without PP1C also being bound to SHOC2 and MRAS, however, the catalytic activity is much slower and the reaction is less efficient. In order for NTpS to bind PP1C in the absence of the other two proteins, NTpS would need to be exposed from its binding site in the inactive RAF complex. RAS has to bind to RAF to expose the NTpS, allowing PP1C and NTpS to bind.
Figure 3. Schematic representation of RAF activation. PP1C removes an inhibitory phosphate group from RAF, which results in RAF activation and activation of the RAF/MAPK signaling cascade.
Once the SMP complex comes together, it plays a key role in regulating the activation of the RAF/MAPK pathway. PP1C, enhanced through interactions with SHOC2 and MRAS, removes a phosphate group from serine residue 259 (also known as NTpS) of RAF. The removal of the phosphate group triggers activation of RAF, a serine/threonine kinase, which leads to the phosphorylation and activation of MAPK. This causes the activation of downstream proteins ERK1 and ERK2, which are responsible for activating nuclear transcription factors such as Elk-1, c-Ets1, C-Ets2, and MNK1, which result in the transcription of genes that code for proteins which promote cell proliferation and differentiation. [11].
Implications
The SHOC2-MRAS-PP1C complex's key role in the regulation of the MAPK-RAF pathway means that minor changes in its structure or function can have drastic biological consequences. Unregulated activation of the MAPK pathway is the cause of several human cancers due to unchecked cell division and proliferation[8]. Mutations that stabilize the interactions of the SMP complex enhance PP1C phosphatase activity [9], leading to increased RAF signaling and accelerated cell division. Most SHOC2 or PP1C mutations alter residues that are the direct contact points, stabilizing the interaction between the two proteins. Mutations to MRAS result in persistent binding of GTP, leading to consistent activation of the cell signaling pathway[8].
The unregulated MAPK pathway is also responsible for a multitude of developmental disorders commonly known as RASopathies[11]. One RASopathy caused by the mutation of a RAF kinase is known as Noonan Syndrome (NS), which enhances complex formation by stabilizing the interactions of each member[8]. NS is a genetic disorder that can prevent normal development during the neonatal period, leading to difficulties with feeding and a failure to thrive[12]. The characteristic features of NS become more evident during infancy and childhood. NS patients often have atypical facial appearance, short stature, heart defects, and other physical problems[12].
↑ 1.01.1Bernal Astrain G, Nikolova M, Smith MJ. Functional diversity in the RAS subfamily of small GTPases. Biochem Soc Trans. 2022 Apr 29;50(2):921-933. doi: 10.1042/BST20211166. DOI:10.1042/BST20211166
↑Li, L., Zhao, G. D., Shi, Z. et. al.The Ras/Raf/MEK/ERK signaling pathway (Figure 1) and its role in the occurrence and development of HCC. Oncology letters, 12(5), 3045–3050. DOI:10.3892/ol.2016.5110.
↑ 4.04.14.2Hauseman, Z.J., Fodor, M., Dhembi, A. et al. Structure of the MRAS–SHOC2–PP1C phosphatase complex. Nature 609, 416–423 (2022). doi: 10.1038/s41586-022-05086-1. DOI:10.1038/s41586-022-05086-1.
↑ Kwon, J. J., & Hahn, W. C. A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Molecular and cellular biology, 41(4), e00627-20 (2021). doi:10.1128/MCB.00627-20. DOI: 10.1128/MCB.00627-20.
↑Young, L., Rodriguez-Viciana, P. MRAS: A Close but Understudied Member of the RAS Family. Cold Spring Harbor Perspectives in Medicine (2018). doi: 10.1101/cshperspect.a033621. DOI: 0.1101/cshperspect.a033621.
↑Daniel A. Bonsor, Patrick Alexander, Kelly Snead, Nicole Hartig, Matthew Drew, Simon Messing, Lorenzo I. Finci, Dwight V. Nissley, Frank McCormick, Dominic Esposito, Pablo Rodrigiguez-Viciana, Andrew G. Stephen, Dhirendra K. Simanshu. Structure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndrome. bioRxiv. 2022.05.10.491335. doi: 10.1101/2022.05.10.491335. DOI:10.1101/2022.05.10.491335.
↑ 8.08.18.28.38.4Kwon, J.J., Hajian, B., Bian, Y. et al. Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex. Nature 609, 408–415 (2022).doi: 10.1038/s41586-022-04928-2. DOI:10.1038/s41586-022-04928-2
↑ 9.09.19.2Kwon, J., Jajian, B., Bian, Y. et al. Comprehensive structure-function evaluation of the SHOC2 holophosphatase reveals disease mechanisms and therapeutic opportunities. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022. DOI: 10.1158/1538-7445.AM2022-LB029.
↑Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J. Structural basis for SHOC2 modulation of RAS signalling. Nature. 2022 Jun 29. pii: 10.1038/s41586-022-04838-3. doi:, 10.1038/s41586-022-04838-3. PMID:35768504 doi:https://dx.doi.org/10.1038/s41586-022-04838-3
